Have some news you want to share with the Oregon Bio community? Fill out our submission form.
Oregon Bio has launched an occasional series called Voice of Academia and today, we’re bringing Part 2 (see Part 1 here) of our talk with University of Oregon professor and faculty member at the Phil and Penny Knight Campus for Accelerating Scientific Impact, Keat Ghee Ong, Ph.D. Dr. Ghee launched the Ong Lab as well as Penderia Technologies, Inc. and here, he explains his work starting up:
Q: How has Knight Campus programming supported your efforts […]
Current growth in bioscience and medtech sectors drives upward demand for industry-vetted BioPro education
(Portland, Ore.) – With hiring and growth happening at dozens of scientific, manufacturing and biotech companies in the Pacific Northwest, the Oregon Bioscience Association has retooled its myriad educational workforce training, classes and workshops to now be offered online live with industry-expert instructors, through its well-known BioPro program.
The recently released Biotechnology Innovation Organization/TEConomy 2020 report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State and Local Communities, analyzes the bioscience industry’s economic footprint across the nation and in Oregon. […]
June 29, 2020
In the weeks since we learned of remdesivir’s potential against COVID-19, one topic has attracted more speculation than any other: what price we might set for the medicine. This degree of speculation is understandable. Remdesivir, our investigational treatment, is the first antiviral to have demonstrated patient improvement in clinical trials for COVID-19 and there is no playbook for how to price a new medicine in a pandemic. We are aware of the significant responsibility that comes with pricing […]
Voice of Academia: Part 1 – Driving toward student career paths’ diversity and the launch of UO’s new science campus
Oregon Bio has launched an occasional series called Voice of Academia to spotlight academic partnerships and commercialization opportunities as well as advances in research in the Pacific Northwest’s bioscience and medical technology ecosystem. In this profile, we explore the talented bench at UO’s new science campus and how a company is spinning off to meet global demand for implantable and wireless sensors, electronic devices and magneto-elastic materials.
At the University of Oregon, we recently interviewed a professor and faculty member at the Phil […]
Washington, DC – (June 26, 2020) – The Biotechnology Innovation Organization (BIO) today announced winners of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 30 finalists were evaluated by expert judges with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors. A total of five winners were chosen across three groups. Competitors from around the globe were judged on the strength of their commercially viable […]
The show will go on!” says AdvaMed CEO Scott Whitaker
WASHINGTON, D.C. – The MedTech Conference, powered by AdvaMed, promises to continue its tradition of providing world-class programming for the medical technology community, announcing today that the conference will be an all-virtual experience for 2020, and that its plan to host the conference in Toronto will be pushed to 2022.
“The MedTech Conference is the premier annual gathering of our industry, and it is more important than ever that we show, despite […]
Gazelle® Diagnostic Platform, Designed for Low Resource Settings, Integrates Miniaturized Technologies with AI to Transform Disease Screening and Diagnosis
● 8-Minute, Low-Cost Diagnostic Test for Sickle Cell Disease (SCD) Among First Approved Tests
● Includes a One-Minute Malaria Test with Solutions to Follow for Other Health Priorities
Officials from Hemex Health in Portland and Mumbai were joined by global health thought leaders in anticipation of World Sickle Cell Day by launching the company’s Gazelle® Diagnostic platform. Gazelle features a Sickle Cell Disease (SCD) test that has CE Mark and regulatory approval in India and Ghana with other country registrations pending.
“We describe […]
Autobahn Therapeutics launches with $76 million Series B financing to develop next generation therapies for CNS disorders
Financing Co-Led by ARCH Venture Partners and Cowen Healthcare Investments
Deep Leadership Expertise in Thyroid Hormone Biology, Medicinal Chemistry and Neurology
SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics is launching to create the next generation of regenerative medicines to restore hope for people affected by CNS disorders. The company has completed a $76 million Series B fundraising co-led by ARCH Venture Partners and Cowen Healthcare Investments, with participation from BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, […]
Oregon Translational Research and Development Institute and Oregon Bioscience Incubator name new executive director
Board of directors selects interim director Heather Ellis to take full time role
June 10, 2020 — PORTLAND, Ore. — The board of directors for the Oregon Translational Research and Development Institute (OTRADI) and Oregon Bioscience Incubator (OBI) (https://otradi.org/) announced today that Heather Ellis, former interim executive director for the organization, has been promoted to the position of full-time executive director for OTRADI and
“Over the past three years, we have admired and appreciated Heather’s exceptional work at OTRADI and OBI, including […]
ERT, the global leader in clinical endpoints data collection, today announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement.
Current clinical trial assessments in movement disorders such as Parkinson’s disease (PD), Multiple Sclerosis (MS), and Ataxia are subjective and based on episodic visits. Consequently, […]